WAY 123398
Latest Information Update: 06 Oct 2011
Price :
$50 *
At a glance
- Originator Wyeth
- Class Class III antiarrhythmics
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arrhythmias
Most Recent Events
- 02 Apr 1997 No-Development-Reported for Arrhythmias in USA (Unknown route)
- 24 Oct 1994 Preclinical development for Arrhythmias in USA (Unknown route)